Optimizing Response in Psychosis Study

PHASE4TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
SchizophreniaSchizoaffective DisorderSchizophreniform DisorderPsychotic Disorder Not Otherwise Specified
Interventions
DRUG

long-acting injectable risperidone

One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.

Trial Locations (2)

11004

The Zucker Hillside Hospital, Glen Oaks

11203

SUNY Downstate Medical Center, Brooklyn

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The Zucker Hillside Hospital

OTHER

collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

lead

Northwell Health

OTHER